Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May-Jun;100(3):602-605.
doi: 10.1016/j.abd.2024.11.003. Epub 2025 Apr 28.

Pyoderma gangrenosum diagnosed in a high-risk myelodysplastic neoplasm patient with trisomy 8: a rare case report

Renato Mendes Martins  1 , Howard Lopes Ribeiro-Junior  2 , Natália Feitosa Arrais Minete Mendonça  3 , Fábio Rocha Fernandes Távora  4 , Ronald Feitosa Pinheiro  5
Affiliations

Pyoderma gangrenosum diagnosed in a high-risk myelodysplastic neoplasm patient with trisomy 8: a rare case report

Renato Mendes Martins et al. An Bras Dermatol. 2025 May-Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest None declared.

Figures

Fig. 1
Fig. 1
Karyotype analysis of elderly female myelodysplastic neoplasm/syndrome patient demonstrating 47,XX,+8[11]/46,XX[1].
Fig. 2
Fig. 2
Lesion ulcerative with violaceous aspect on borders consistent with pyoderma gangrenosum diagnosis.
Fig. 3
Fig. 3
Histologic section of skin showing hyperkeratosis in the stratum corneum. The epidermis exhibits mild acanthosis. The dermis shows moderate inflammatory infiltrate characterized by lymphoplasmacytic leucocytes, with significant associated tissue hemorrhage. There is mild perivascular inflammation, without evidence of vasculitis. Absence of edema in the papillary dermis. (A) Low power of the histological section of skin demonstrating hyperkeratosis, mild inflammation and hemorrage. (B) Hyperkeratosis in the stratum corneum and mild acanthosis in the epidermis. (C) Moderate inflammatory infiltrate with a perivascular distribution and with tissue hemorrhage in the dermis. Hematoxylin & eosin staining.
Fig. 4
Fig. 4
Pyoderma gangrenosum lesion regression after dapsone treatment.
See this image and copyright information in PMC

References

    1. Barbe M., Batra A., Golding S., Hammond O., Higgins J.C., O’Connor A., et al. Pyoderma gangrenosum: a literature review. Clin Podiatr Med Surg. 2021;38:577–588. - PubMed
    1. Maronese C.A., Pimentel M.A., Li M.M., Genovese G., Ortega-Loayza A.G., Marzano A.V. Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol. 2022;23:615–634. - PMC - PubMed
    1. Montagnon C.M., Fracica E.A., Patel A.A., Camilleri M.J., Murad M.H., Dingli D., et al. Pyoderma gangrenosum in hematologic malignancies: a systematic review. J Am Acad Dermatol. 2020;82:1346–1359. - PubMed
    1. Pinheiro R.F., Metze K., Silva M.R., Chauffaille Mde L. The ambiguous role of interferon regulatory factor-1 (IRF-1) immunoexpression in myelodysplastic syndrome. Leuk Res. 2009;33:1308–1312. - PubMed
    1. Drevon L., Marceau A., Maarek O., Cuccuini W., Clappier E., Eclache V., et al. Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies. Br J Haematol. 2018;182:843–850. - PubMed

LinkOut - more resources